Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome

Raffaella Greco; Jacopo Peccatori; Francesca Bonifazi; John A Snowden; Fabio Ciceri

doi:10.3389/fimmu.2021.670822

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome

Front Immunol. 2021 Mar 12:12:670822. doi: 10.3389/fimmu.2021.670822. eCollection 2021.

Authors

Raffaella Greco¹, Jacopo Peccatori¹, Francesca Bonifazi², John A Snowden^{3

4}, Fabio Ciceri^{1

5}

Affiliations

¹ Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
² Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
³ Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
⁴ Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
⁵ University Vita-Salute San Raffaele, Milan, Italy.

No abstract available

Keywords: allogeneic transplantation; biomarkers; cytokines; graft-versus-host disease; immunological biomarkers; outcomes; proteins; transplant-related mortality.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Biomarkers
Chimerism
Graft vs Host Disease / immunology*
Hematologic Diseases / therapy*
Hematopoietic Stem Cell Transplantation*
Humans
Immune Tolerance
Immunity
Transplantation, Homologous
Treatment Outcome

Substances

Biomarkers